Tech Company Financing Transactions
Proteolix Funding Round
Proteolix, based in South San Francisco, received $45 million from Delphi Ventures, Advanced Technology Ventures and Latterell Venture Partners.
Transaction Overview
Company Name
Announced On
5/31/2006
Transaction Type
Venture Equity
Amount
$45,000,000
Round
Series B
Investors
Delphi Ventures (Lead Investor) (Deepa Pakianathan)
Latterell Venture Partners (Larry Lasky)
Proceeds Purpose
The new capital will be used to expand the Company's on-going clinical trials of the novel proteasome inhibitor PR-171 in cancer and support the development of its pipeline.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
333 Allerton Avenue
South San Francisco, CA 94080
USA
South San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Proteolix, Inc. is a biopharmaceutical company dedicated to discovering, developing and marketing pharmaceutical products that target the proteasome and the control of protein turnover in cells. The company's focus is on the treatment of cancer, inflammatory disease, and autoimmunity.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Medical Officer
Michael Kauffman
Executive Vice President
Thomas Kassberg
Vice President
Mark Bennett
Vice President
Christopher Molineaux
VP - Finance
Craig Parker
VP - Regulatory Affairs
Albert Kraus
Browse more venture capital transactions:
Prev: 5/31/2006: Krugle venture capital transaction
Next: 5/31/2006: Tesla venture capital transaction
Share this article
About Database of VC Transactions
We report on all VC transactions involving tech companies. VC transactions on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs